HIMS
New face, same telehealth hustle
Hims & Hers just tapped Anant Vinjamoori as its chief medical officer, and Wall Street promptly noticed. The market tends to love a leadership hire when it can be spun as strategic, and this one comes with a nice package: longevity medicine, preventive care, and a pitch that the company is building out a deeper medical bench.
Why investors are leaning in
The company is selling more than a résumé here. It’s signaling that it wants to look less like a trendy telehealth app and more like a broad, science-driven care platform. That matters because Hims is trying to keep expanding beyond the usual headline-grabbing categories and into a bigger healthcare umbrella.
A few things to keep on your radar:
- The stock was up about 7.23% at $29.50 around publication time.
- HIMS is still down sharply over the past year, so this is more “bounce off the mat” than “victory lap.”
- The shares are above their shorter-term moving averages, which is the chart equivalent of finally sitting up straight after a rough nap.
The catch: one appointment doesn’t fix the whole chart
Even with today’s jump, Hims is still below its 200-day moving average, and that lingering death cross from December 2025 hasn’t magically disappeared like a bad haircut. In other words, the market likes the story, but it hasn’t fully bought the sequel yet.
Big picture: this is a classic “show me” rally. The new medical leadership may help sharpen Hims’ brand and credibility, but investors will want follow-through before declaring the comeback tour officially on the road.